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Manuscript
 We read with interest the recent MUSCA trial from Chupp and colleagues
1
 which concluded that 
mepolizumab was associated with significant improvements in health related quality of life (QOL) in 
patients with severe eosinophilic asthma (SEA) and therefore support its use as a favourable add-on 
treatment option to standard of care. Unfortunately there are several issues with the minimum clinically 
important difference (MCID) for the presented data which make this conclusion untenable. 
The primary outcome of the St George’s Respiratory Questionnaire (SGRQ) was specially designed for 
use in COPD rather than asthma
2
, whereas the disease specific asthma quality of life questionnaire 
(AQLQ) is more appropriate to patients with asthma
3
. At end point after 24 weeks the mean change in 
SGRQ total score was -7·7 which although statistically significant only amounted to a “slightly 
effective” change (MCID >-4·0), but less than the MCID thresholds for a “moderately effective” 
change (>-8·0) or  a “very effective” change (>-12)4. There appeared to be no difference in effects of 
mepolizumab on SGRQ according to low or high blood eosinophil counts, in turn suggesting that they 
chose the wrong QOL instrument for patients with SEA. 
Moreover the 120 ml mean improvement in FEV1 was less than the MCID of 230ml
5
, while the mean 
change in asthma control questionnaire (ACQ) of -0·4 was also less than the MCID of -0·5
3
. For 
comparison in a study with dupilumab after 12 weeks there were mean improvements in ACQ (-0·73) 
and FEV1 (0·27) which both exceeded their respective MCID’s6. 
These findings all point to a statistically significant but clinically meaningless impact on quality of life, 
lung function and asthma control. Prescribers therefore need to be aware when following SEA patients 
with mepolizumab that its effects in reducing exacerbations may be disconnected from these other 
important clinical outcomes. 
It is also worth noting that the MUSCA trial excluded patients who smoked, which means the findings 
may not be pertinent to more deprived areas where smoking is highly prevalent among asthma patients. 
Finally their cohort exhibited a mean reversibility to salbutamol of 21%, which in our experience is 
unusually high for patients with severe asthma. Hence we would have reservations that these findings 
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